Upcoming Courses
Psychopharmacology, 2015: A Master Class
Ross J. Baldessarini, MD, DSc. (hon), Barbara Coffey, MD, MS, Hilary Connery, MD, PhD, Frederick Goodwin, MD, Jeffrey Lieberman, MD, Charles Nemeroff, MD, PhD, Carl Salzman, MD, Alan Schatzberg, MD, David Sheehan, MD, MBA, Stephen Stahl, MD, PhD, Daniel Weinberger, MD, John Winkelman, MD, PhD, Kimberly Yonkers, MD
This unique two-day course is designed for the experienced clinician. The objectives of this course are to provide, in a lecture and question and answer format, a review of the mechanisms and clinical applications of psychotropic drug treatments with particular emphasis on difficult-to-treat patients. Course participants will be expected to have had clinical experience, familiarity with the neurobiological and genetic contributions to psychiatric illnesses as well as an understanding of the basic therapeutic mechanisms of psychotropic medications. There will be considerable opportunity for interaction with the presenters.
This conference will focus on the following topics: An updated review of neurobiology and brain function will be presented, taking the attendee through neurotransmission sequence from neurotransmitter and synaptic function synthesis to gene transcription. The interaction between genes and the environment will be emphasized. The current use of antipsychotic drugs and mood stabilizing drugs for the treatment of schizophrenia and bipolar disorder will be presented; new antipsychotic medications will also be discussed along with potential new uses for mood stabilizers. A comprehensive review of the neurobiology and genetic predisposition to depression will be emphasized along with the modern use of antidepressants based on the latest research findings. Treatment of Bipolar Depression will be emphasized. The neurobiological mechanisms of anxiety and anxiety-spectrum disorders as well as their treatment will be reviewed, including obsessive-compulsive disorder, panic disorder, social anxiety disorder, PTSD, and general anxiety disorder. The neurobiological mechanisms of stress will also be emphasized. The importance of the evaluation and psychopharmacological treatment of women’s mental health issues will be featured with particular emphasis on PMS, perinatal, and postpartum disorders. The course will also include a review of the role of psychopharmacology in the treatment of sleep disorders. Advances in the neurobiology and treatment of alcohol and substance abuse disorders will be highlighted. The latest advances in child, adolescent and geriatric psychopharmacology will be emphasized. Throughout the course the establishment and importance of the therapeutic alliance when prescribing all psychotropic medications will be underscored, as will the potential hazards/benefits of polypharmacy drug interactions.
- Evaluate the effects of neurotransmitters and genes on psychotropic drug treatment;
- Describe the pharmacologic treatment of schizophrenia with particular reference to the prodromal period and first episode;
- Outline the emerging theories and treatments of bipolar disorder, depression, bipolar depression, stress and anxiety disorder;
- Discuss the role of psychotropic medications in women’s mental health with an emphasis on PMS, pregnancy, nursing, and the postpartum period;
- Review the appropriate use of medications in the treatment of sleep disorders;
- Assess the role of psychopharmacology in the treatment of substance use disorders with particular emphasis on alcohol, opiates, and cannabis;
- Describe the latest advances and problems associated with treatment approaches in the child, adolescent and geriatric populations.
Additional Information
| Friday April 24, 2015 | |||
| 7:48-8:15 am | Registration | ||
| 8:15-8:20 am | Welcome and Overview Carl Salzman, MD |
||
| 8:20-9:05 am | How the Brain Works: Neurons, Synapses, Genes Pathways… Implications for Psychopharmacology Carl Salzman, MD |
||
| 9:05-9:40 am | The Genetic Origins of Psychiatric Disorders; Implications for Treatment? Daniel Weinberger, MD |
||
| 9:40-10:25 am | Treatment of Schizophrenia: What Are We Doing and For Which Patients? Jeffrey Lieberman, MD |
||
| 10:25-11:00 am | Coffee Break | ||
| 11:00-11:45 am | Treatment of PTSD and Stress Disorders Charles Nemeroff, MD, PhD |
||
| 11:45 am-12:00 pm | Panel Discussion and Q&A Carl Salzman, MD, Daniel Weinberger, MD Jeffrey Lieberman, MD, Charlie Nemeroff, MD |
||
| 12:00-1:15 pm | Lunch (on your own) | ||
| 1:15-2:00 pm | Tricks of the Trade: Treatment for Resistant Mood, Anxiety or Psychotic Disorders Stephen M. Stahl, MD, PhD |
||
| 2:00-2:45 pm | Diagnosis and Advances in the Treatment of Bipolar Depression Ross J. Baldessarini, MD, DSc. (hon) |
||
| 2:45-3:00 pm | Coffee Break | ||
| 3:00-3:45 pm | Treatment Resistant Depression: Current Strategies Alan Schatzberg, MD |
||
| 3:45-4:30 pm | Treatment and Maintenance of Bipolar Disorder Frederick Goodwin, MD |
||
| 4:30-5:15 pm | Panel Discussions Frederick Goodwin, MD, Alan Schatzberg, MD and Ross J. Baldessarini, MD, DSc. (hon) |
||
| Saturday April 25, 2015 | |||
| 8:30-9:15 am | Effective Psychotropic Drug Treatment of Anxiety and Anxiety-Spectrum Disorders David Sheehan, MD, MBA |
||
| 9:15-10:00 am | Diagnosis and Treatments of Sleep Disorders John Winkelman, MD, PhD |
||
| 10:00-10:30 am | Coffee Break | ||
| 10:30-11:15 am | Diagnosis and Treatment of Substance Abuse: Alcohol, Opiates, Cannabis Hilary Connery, MD, PhD |
||
| 11:15 am-12:00 pm | Panel Discussion David Sheehan, MD, MBA, John Winkelman, MD, PhD and Hilary Connery, MD, PhD |
||
| 12:00-1:15 pm | Lunch | ||
| 1:15-2:00 pm | The Roles of Antidepressants in the Life Cycle of Women Kimberly Yonkers, MD |
||
| 2:00-2:45 pm | Psychotropic Drug Treatment of Children and Adolescents Barbara Coffey, MD, MS |
||
| 2:45-3:00 pm | Coffee Break | ||
| 3:00-3:45 pm | Safe and Effective Use of Psychotropic Drugs in the Elderly Carl Salzman, MD |
||
| 3:45-4:30 pm | Panel Discussion Kimberly Yonkers, MD, Barbara Coffey, MD, MS and Carl Salzman, MD |
||
| 4:30 pm | Adjourn | ||
Beth Israel Deaconess Department of Psychiatry Foundation, Inc./Contact Hours: 12.5
Accreditation:
The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Harvard Medical School designates this live activity for a maximum of 12.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Royal College of Physicians and Surgeons of Canadarecognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.
AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for AMA PRA Category 1 Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits(ECMEC©) granted by the UEMS. One AMA PRA Category 1 Credit™ is equivalent to one (1) hour of European EACCME Credit (ECMEC©), therefore up to 12.5 ECMEC© Credits are available. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Psychologists: The Continuing Education Program at Beth Israel Deaconess Medical Center, a major
teaching hospital of Harvard Medical School is approved by the American Psychological Association to offer
continuing education for psychologists. The Continuing Education Program at Beth Israel Deaconess Medical
Center, a major teaching hospital of Harvard Medical School maintains responsibility for the program.
Nurses: This continuing nursing education activity was approved by the Massachusetts Association of
Registered Nurses, Inc., an accredited approver by the American Nurses Credentialing Center’s Commission
on Accreditation.